Neuraminidase Inhibitors Drug Market - Top Companies and Manufacturers

  • Report ID: 2563
  • Published Date: Oct 15, 2024
  • Report Format: PDF, PPT

Companies Dominating the Neuraminidase Inhibitors Drug Landscape

    • F. Hoffmann La Roche
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • GlaxoSmithKline plc
    • Gilead Sciences
    • Daiichi Sankyo
    • BioCryst Ltd.

Browse Key Market Insights with Data Illustration:

In the News

  • 17 April, 2020:F. Hoffmann La Roche developed serology test for the detection of presence of COVID- 19 in humans who have been exposed to the disease. Antibody testing is crucial for testing people who do not show any symptoms of the disease.


Author Credits:  Radhika Pawar


  • Report ID: 2563
  • Published Date: Oct 15, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of neuraminidase inhibitors drug is estimated at USD 103.45 billion.

Neuraminidase Inhibitors Drug Market size was over USD 98.04 billion in 2023 and is anticipated to cross USD 233.41 billion by 2036, witnessing more than 6.9% CAGR during the forecast period i.e., between 2024-2036.

North America industry is set to dominate majority revenue share by 2036, as the region is highly developed since the technological advancement is rapid along with good infrastructure.

The major players in the market are F. Hoffmann La Roche, GlaxoSmithKline plc, Gilead Sciences, Daiichi Sankyo, BioCryst Ltd., and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample